Y-chromosome variation in Basrah population.

J Med Life

Biology Department, College of Science, University of Basrah, Basrah, Iraq.

Published: February 2022

Y-chromosome DNA profiles are promising tools in population genetics and forensic science. Analysis of Y-chromosome variety was performed on a total of 191 unrelated males throughout different regions in Basrah. The Y-chromosome variety was explored utilizing 17 markers system. For the uniparental system, the large majority of the haplogroups observed in the Basrah population are (R1b, E1b1b, G2a, and J1) considered to have begun in the Middle East and to have later spread all over Western Eurasia. 30% of the Y-chromosomes, in all likelihood, represent landings from inaccessible distant geographic regions. The level of haplotype diversity and its implication for statistics are evaluated. The distinctive extent of long go genetic input observed for the Y chromosome shows that gene flow events to this area might have involved mainly males.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999105PMC
http://dx.doi.org/10.25122/jml-2021-0281DOI Listing

Publication Analysis

Top Keywords

basrah population
8
y-chromosome variety
8
y-chromosome
4
y-chromosome variation
4
variation basrah
4
population y-chromosome
4
y-chromosome dna
4
dna profiles
4
profiles promising
4
promising tools
4

Similar Publications

Background And Objectives: Dyslipidemia is prevalent among patients with chronic kidney disease on maintenance hemodialysis. A high LDL is a known indicator of major adverse cardiovascular outcomes, but levels may be affected by malnutrition. A high TG/HDL ratio is another indicator of hard cardiovascular outcomes that should be sought carefully.

View Article and Find Full Text PDF

Key Clinical Message: The discovery of compound heterozygous mutations (c.245T>C; p.Val82Ala and c.

View Article and Find Full Text PDF
Article Synopsis
  • - Resmetirom, a selective thyroid hormone receptor-β agonist, shows potential in treating non-alcoholic steatohepatitis (NASH), a major cause of liver-related health issues globally.
  • - A systematic review and meta-analysis indicated that Resmetirom significantly reduced low-density lipoprotein cholesterol (LDL-C) and alanine aminotransferase (ALT) levels compared to a placebo, although it also increased the risk of side effects like diarrhea and nausea.
  • - Overall, Resmetirom appears to be a promising option for improving liver health in NASH patients, potentially filling a gap in current treatment strategies.
View Article and Find Full Text PDF

Introduction: Differentiated thyroid cancer (DTC), the most common endocrine malignancy is subdivided into papillary (the most common) and follicular type. Generally, DTC has a good prognosis with standard treatments such as surgery and, in some cases, radioactive iodine (RAI). Post-treatment follow-up includes thyroglobulin (Tg) and anti-thyroglobulin antibody (TgAb) measurement and imaging to assess treatment success and detect recurrence.

View Article and Find Full Text PDF

Background Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases caused by the accumulation of fat in the liver, which can progress to fibrosis, cirrhosis, and primary liver cancer. Insulin resistance is a causative factor in the development of NAFLD. FibroScan, or transient elastography, is a noninvasive imaging technique for evaluating liver disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!